Novartis Reports Long-Term Val-HeFT Data for Valsartan in Heart Failure

Novartis today presented long-term follow-up data from the Val-HeFT trial evaluating valsartan in patients with heart failure. The data showed that valsartan maintained significant reductions in cardiovascular mortality and morbidity over long-term follow-up, with the greatest benefit observed in patients not receiving ACE inhibitors.